In summary, arteries become hardened and non-elastic as atherosclerosis develops. EDTA chelation therapy “softens” these hardened arteries by reducing the collagen and elastin cross linkages by removing the metals that are generating the cross-linking free radicals.
Pyridoxine (Vitamin B6)
Chelation is gaining acceptance in conventional medicine as an adjunct treatment for Alzheimer’s Disease. By removing unbound iron, copper, aluminum, zinc, etc. in the brain, which generate free radicals and contribute to the development of collagen and elastin cross linking by free radicals (as advanced glycation end products), chelation assists in blocking the factors that contribute to diabetes, atherosclerosis, neurodegenerative diseases including Alzheimer’s, and aging.
In addition the NIH conducted a multicenter medical trial with EDTA chelation for atherosclerosis. Previous studies were flawed in that the ACAM protocol was not followed. There is also the need for the drip to be sufficiently slow and for the patient’s blood to be checked through the week to insure that essential minerals are maintained within the normal range.
Hydroxycobalamin (Vitamin B12)
When this study was completed, the results were summarized as follows:
“A $30 million National Institutes of Health-funded trial to assess the safety and efficacy of EDTA chelation therapy in 1708 post-myocardial infarction (MI) patients was completed in 2014. The trial demonstrated a significant (P=0.035) 18% reduction in a combined primary endpoint of death, MI, stroke, coronary revascularization or hospitalization of angina. In diabetic patients the benefit was more impressive, with a 41% relative reduction in risk (P=0.0002) and a 43% reduction in total mortality (P=0.011). Safety data were also favorable. A reduction of oxidative stress by chelation of toxic metals has been proposed as a possible mechanism of action.”